We did not observe a significant increase in hsCRP levels in thrombocytosis cases with JAK2-V617F mutations compared with cases without mutant JAK2, but this may likely be explained by the smaller clone sizes in our cohort compared with MPN cases.33 The gene discussed is JAK2; the disease is myeloproliferative neoplasm.